A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
Public ClinicalTrials.gov record NCT03100149. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 11-Year All-Participants-on-Treatment Extension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of three parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2). Participants who complete Part 2 (including the 12-week treatment-free follow up visit assessing long term safety and efficacy of RO7046015) will be offered participation in Part 3 open-label extension (all-participants-on-RO7046015-treatment) for an additional 520 weeks.
Study identification
- NCT ID
- NCT03100149
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 316 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 27, 2017 (Actual)
- Primary completion
- Nov 27, 2019 (Actual)
- Completion
- Dec 1, 2031 (Estimated)
- Last update posted
- Sep 11, 2026
2017 – 2031
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Uab Medicine | Birmingham | Alabama | 35233 | — |
| Barrow Neurology Clinics | Phoenix | Arizona | 85013 | — |
| Neurology Center of North Orange County | Fullerton | California | 92835 | — |
| USC Keck Medical Center of USC | Los Angeles | California | 90033 | — |
| University of California at San Francisco | San Francisco | California | 94115 | — |
| CenExel Rocky Mountain Clinical Research, LLC | Englewood | Colorado | 80113 | — |
| Associated Neurologists of Southern CT PC | Fairfield | Connecticut | 06824 | — |
| Molecular Neurolmaging | New Haven | Connecticut | 06510 | — |
| Aventura Neurologic Associates | Aventura | Florida | 33180 | — |
| Parkinson's Disease and Movement Disorders Center of Boca Raton | Boca Raton | Florida | 33486 | — |
| USF Parkinsons Disease and Movement Disorders Center | Tampa | Florida | 33613 | — |
| Northwestern University | Evanston | Illinois | 60208 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Quest Research Institute | Farmington Hills | Michigan | 48334 | — |
| Corewell Health Neurology and Epilepsy - Beltline | Grand Rapids | Michigan | 49525 | — |
| Henry Ford Health System | West Bloomfield | Michigan | 48322 | — |
| Columbia University | New York | New York | 10032 | — |
| University of Rochester Medical Center | Rochester | New York | 14618 | — |
| The Movement Disorder Clinic of Oklahoma | Tulsa | Oklahoma | 74136 | — |
| Oregon Health & Science Uni | Portland | Oregon | 97239 | — |
| UNIVERSITY of PENNSYLVANIA | Philadelphia | Pennsylvania | 19107 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Baylor College | Houston | Texas | 77030 | — |
| Central Texas Neurology Consultants | Round Rock | Texas | 78681 | — |
| University of Vermont Medical Center | Burlington | Vermont | 05401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03100149, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 11, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03100149 live on ClinicalTrials.gov.